FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792539640> ?p ?o ?g. }

• W2792539640 endingPage "8164" @default.
• W2792539640 startingPage "8155" @default.
• W2792539640 abstract "// Bernhard Josef Eigl 1 , Kim Chi 1 , Dongsheng Tu 2 , Sebastien J. Hotte 3 , Eric Winquist 4 , Christopher M. Booth 5 , Christina Canil 6 , Kylea Potvin 4 , Richard Gregg 2 , Scott North 7 , Muhammad Zulfiqar 1 , Susan Ellard 8 , Joseph Dean Ruether 9 , Lyly Le 10 , A. Saranya Kakumanu 11 , Mohammad Salim 12 , Alison L. Allan 4 , Harriet Feilotter 2 , Ashley Theis 2 and Lesley Seymour 2 1 BC Cancer Agency, Vancouver, BC, Canada 2 Canadian Cancer Trials Group, Kingston, ON, Canada 3 Juravinski Cancer Centre, Hamilton, ON, Canada 4 London Health Sciences Centre, London, ON, Canada 5 Cancer Centre of Southeastern Ontario, Kingston, ON, Canada 6 Ottawa Regional Cancer Center, Ottawa, ON, Canada 7 Cross Cancer Centre, Edmonton, AB, Canada 8 BC Cancer Agency, Kelowna, BC, Canada 9 Tom Baker Cancer Centre, Calgary, AB, Canada 10 BC Cancer Agency, Surrey, BC, Canada 11 Cancer Care Manitoba, Winnipeg, MB, Canada 12 Regina Cancer Centre, Regina, SK, Canada Correspondence to: Bernhard Josef Eigl, email: Bernie.eigl@bccancer.bc.ca Keywords: prostate cancer; oncolytic viruses; chemotherapy; clinical trial Received: October 12, 2017     Accepted: January 02, 2018     Published: January 17, 2018 ABSTRACT Background: Pelareorep is an oncolytic virus with activity in many cancers including prostate. It has in vitro synergism with microtubule-targeted agents. We undertook a clinical trial evaluating pelareorep in mCRPC patients receiving docetaxel. Patients and Methods: In this randomized, open-label phase II study, patients received docetaxel 75mg/m 2 on day 1 of a 21-day cycle and prednisone 5mg twice daily, in combination with pelareorep (arm A) or alone (arm B). The primary endpoint was 12 weeks lack of disease progression rate (LPD). Results: Eighty-five pts were randomized. Median age was 69, ECOG performance status was 0/1/2 in 31%/66%/3% of patients. Bone/regional lymph node/liver metastases were present in 98%/24%/6%. The median prognostic score was slightly higher in Arm A (144 vs. 129 p= 0.005). Adverse events were as expected but more prevalent in arm A. The 12-week LPD rate was 61% and 52.4% in arms A/B (p=0.51). Median survival was 19.1 on Arm A and 21.1 months on Arm B (HR 1.83; 95% CI 0.96 to 3.52; p=0.06). No survival benefit of pelareorep was found. Conclusion: Pelareorep with docetaxel was tolerable with comparable LPD in both arms but response and survival were inferior and so this combination does not merit further study." @default.
• W2792539640 created "2018-03-29" @default.
• W2792539640 creator A5001051024 @default.
• W2792539640 creator A5005231494 @default.
• W2792539640 creator A5008275218 @default.
• W2792539640 creator A5019814247 @default.
• W2792539640 creator A5032075908 @default.
• W2792539640 creator A5037668304 @default.
• W2792539640 creator A5042123586 @default.
• W2792539640 creator A5044291041 @default.
• W2792539640 creator A5046515596 @default.
• W2792539640 creator A5058331275 @default.
• W2792539640 creator A5060092380 @default.
• W2792539640 creator A5061626918 @default.
• W2792539640 creator A5062265839 @default.
• W2792539640 creator A5063121757 @default.
• W2792539640 creator A5067388752 @default.
• W2792539640 creator A5078568032 @default.
• W2792539640 creator A5089306688 @default.
• W2792539640 creator A5089705721 @default.
• W2792539640 creator A5089899558 @default.
• W2792539640 creator A5090221422 @default.
• W2792539640 date "2018-01-17" @default.
• W2792539640 modified "2023-10-17" @default.
• W2792539640 title "A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209" @default.
• W2792539640 cites W1484464171 @default.
• W2792539640 cites W1936207051 @default.
• W2792539640 cites W1980309655 @default.
• W2792539640 cites W1986462840 @default.
• W2792539640 cites W1996550262 @default.
• W2792539640 cites W2019607817 @default.
• W2792539640 cites W2090599158 @default.
• W2792539640 cites W2093231404 @default.
• W2792539640 cites W2103156714 @default.
• W2792539640 cites W2110811665 @default.
• W2792539640 cites W2111954625 @default.
• W2792539640 cites W2113923002 @default.
• W2792539640 cites W2120292596 @default.
• W2792539640 cites W2126015139 @default.
• W2792539640 cites W2139397653 @default.
• W2792539640 cites W2147086299 @default.
• W2792539640 cites W2148998801 @default.
• W2792539640 cites W2159771669 @default.
• W2792539640 cites W2167331614 @default.
• W2792539640 cites W2212208771 @default.
• W2792539640 cites W2316101052 @default.
• W2792539640 cites W2589049499 @default.
• W2792539640 cites W2892012428 @default.
• W2792539640 cites W2917837889 @default.
• W2792539640 doi "https://doi.org/10.18632/oncotarget.24263" @default.
• W2792539640 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5814290" @default.
• W2792539640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29487723" @default.
• W2792539640 hasPublicationYear "2018" @default.
• W2792539640 type Work @default.
• W2792539640 sameAs 2792539640 @default.
• W2792539640 citedByCount "14" @default.
• W2792539640 countsByYear W27925396402019 @default.
• W2792539640 countsByYear W27925396402020 @default.
• W2792539640 countsByYear W27925396402021 @default.
• W2792539640 countsByYear W27925396402022 @default.
• W2792539640 countsByYear W27925396402023 @default.
• W2792539640 crossrefType "journal-article" @default.
• W2792539640 hasAuthorship W2792539640A5001051024 @default.
• W2792539640 hasAuthorship W2792539640A5005231494 @default.
• W2792539640 hasAuthorship W2792539640A5008275218 @default.
• W2792539640 hasAuthorship W2792539640A5019814247 @default.
• W2792539640 hasAuthorship W2792539640A5032075908 @default.
• W2792539640 hasAuthorship W2792539640A5037668304 @default.
• W2792539640 hasAuthorship W2792539640A5042123586 @default.
• W2792539640 hasAuthorship W2792539640A5044291041 @default.
• W2792539640 hasAuthorship W2792539640A5046515596 @default.
• W2792539640 hasAuthorship W2792539640A5058331275 @default.
• W2792539640 hasAuthorship W2792539640A5060092380 @default.
• W2792539640 hasAuthorship W2792539640A5061626918 @default.
• W2792539640 hasAuthorship W2792539640A5062265839 @default.
• W2792539640 hasAuthorship W2792539640A5063121757 @default.
• W2792539640 hasAuthorship W2792539640A5067388752 @default.
• W2792539640 hasAuthorship W2792539640A5078568032 @default.
• W2792539640 hasAuthorship W2792539640A5089306688 @default.
• W2792539640 hasAuthorship W2792539640A5089705721 @default.
• W2792539640 hasAuthorship W2792539640A5089899558 @default.
• W2792539640 hasAuthorship W2792539640A5090221422 @default.
• W2792539640 hasBestOaLocation W27925396401 @default.
• W2792539640 hasConcept C121608353 @default.
• W2792539640 hasConcept C126322002 @default.
• W2792539640 hasConcept C143998085 @default.
• W2792539640 hasConcept C2780192828 @default.
• W2792539640 hasConcept C2781190966 @default.
• W2792539640 hasConcept C71924100 @default.
• W2792539640 hasConcept C74909509 @default.
• W2792539640 hasConceptScore W2792539640C121608353 @default.
• W2792539640 hasConceptScore W2792539640C126322002 @default.
• W2792539640 hasConceptScore W2792539640C143998085 @default.
• W2792539640 hasConceptScore W2792539640C2780192828 @default.
• W2792539640 hasConceptScore W2792539640C2781190966 @default.
• W2792539640 hasConceptScore W2792539640C71924100 @default.
• W2792539640 hasConceptScore W2792539640C74909509 @default.
• W2792539640 hasIssue "8" @default.

• next